DAPAGLIFLOZIN

Clinical Indication

Type 1 diabetes

Comments

Dapagliflozin is no longer licensed for use in T1DM due to commercial reasons. The NICE TA for this indication has been withdrawn. Patients already taking dapagliflozin for this indication should continue.

Date of classification

December 2021

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.